Atlas Trials

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Clinical trial NCT01728324 · COMPLETED

Trial details

NCT number
NCT01728324
Sponsor
Boehringer Ingelheim
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Hepatitis C, Chronic
Start date
2012-11-01
Primary completion
2014-02-01
Enrollment
496

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.